Scarica l'app Stockscreener
149.25
0.69%
1.03
Dopo l'orario di chiusura:
150.00
0.75
+0.50%
Natera Inc Borsa (NTRA) Ultime notizie
Judge Connolly (D. Del.) Overturns $96 Million Molecular Diagnostics Jury Verdict, Finds Patents Invalid Under § 112 - JD Supra
Is Natera, Inc. (NTRA) a Best Biotech Stock According to Billionaires? - Yahoo Finance
Natera: Strong Growth Trajectory Despite Stretched Valuation Metrics (NASDAQ:NTRA) - Seeking Alpha
Natera Inc.: Strong Execution in Revenue Per Test Powering Our Optimism! - Smartkarma
Natera: Solid Execution, Pricey Stock (NASDAQ:NTRA) - Seeking Alpha
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time - Seeking Alpha
Natera Sees Unusually Large Options Volume (NASDAQ:NTRA) - Defense World
RBC Capital initiates Exact Sciences with Sector Perform, Natera with Outperform - MSN
INVESTOR DEADLINE: Natera, Inc. Investors with Substantial Losses Have Opportunity to Lead Natera Class Action Lawsuit – NTRA - Business Wire
Natera director Marcus Gail Boxer sells $590,773 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells $7.39 million in stock By Investing.com - Investing.com Australia
Natera director Marcus Gail Boxer sells $590,773 in stock - Investing.com India
Natera executive chairman sells $7.39 million in stock - Investing.com
Natera And 2 Other Stocks That May Be Trading Below Their Estimated Value - Simply Wall St
Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
RBC Capital Initiates Coverage of Natera (NTRA) with Outperform Recommendation - Nasdaq
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board - Simply Wall St
RBC Initiates Natera at Outperform With $251 Price Target -March 13, 2025 at 06:44 am EDT - Marketscreener.com
Natera initiated with an Outperform at RBC Capital - MSN
Natera Appoints Monica Bertagnolli to Board of Directors - TipRanks
Minimal Residual Disease Market Expected to rise, 2032 | Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., expected to boost the market - Barchart
Natera at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com
Natera's Stock Rebounds Amid Market VolatilityNews and Statistics - IndexBox, Inc.
How Do Investors Really Feel About Natera? - Benzinga
NTRA Shares Rise After Market Rebound - GuruFocus.com
Why Is Natera (NTRA) Stock Soaring Today - MSN
Natera (NASDAQ:NTRA) Upgraded at StockNews.com - Defense World
Natera launches HEROES trial for breast cancer treatment - Investing.com Australia
Natera launches HEROES trial for breast cancer treatment By Investing.com - Investing.com South Africa
Natera enrolls first patients in HEROES clinical trial Metastatic HER2+ BC - TipRanks
Natera Begins Major Clinical Trial for Breast Cancer Therapy Management - StockTitan
Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Non-invasive Prenatal Testing (NIPT) Market Growth and Future - openPR
Natera damages blow; Ozempic patent gold rush; H&M IP strategy; Tesla loses Avanci 5G appeal; International Women’s Day; plus much more - IAM
Natera, Inc. (NASDAQ:NTRA) Stake Increased by Smartleaf Asset Management LLC - Defense World
Solomon Moshkevich Sells 6,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock - Defense World
Steven Leonard Chapman Sells 87,272 Shares of Natera, Inc. (NASDAQ:NTRA) Stock - Defense World
Natera, Inc. (NASDAQ:NTRA) Position Decreased by US Bancorp DE - Defense World
Natera, Inc. to Host Earnings Call - ACCESS Newswire
Natera president sells $859,734 in company stock By Investing.com - Investing.com Canada
Natera president sells $859,734 in company stock - Investing.com
Natera Executives Conduct Significant Stock Sales - TradingView
Morgan Stanley Boosts Natera (NASDAQ:NTRA) Price Target to $185.00 - Defense World
Natera CEO Steven Chapman sells $12.5 million in stock - Investing.com
Piper Sandler Forecasts Strong Price Appreciation for Natera (NASDAQ:NTRA) Stock - Defense World
Natera Set to Continue Upside Surprises During 2025, Beyond, Morgan Stanley Says - Marketscreener.com
Natera price target raised to $185 from $176 at Morgan Stanley - TipRanks
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Natera, Inc. - ACCESS Newswire
Natera’s Strong Financial Performance and Growth Potential Reinforce Buy Rating - TipRanks
Private Advisor Group LLC Has $397,000 Stock Position in Natera, Inc. (NASDAQ:NTRA) - Defense World
Natera (NASDAQ:NTRA) Sees Large Volume Increase Following Analyst Upgrade - Defense World
USPTO issues Natera new patent related to testing of ctDNA - TipRanks
Natera Granted US Patent for Testing Single Nucleotide Variants -March 04, 2025 at 08:05 am EST - Marketscreener.com
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Business Wire
Natera Full Year 2024 Earnings: Beats Expectations - Simply Wall St
Natera’s Strong Market Position and Growth Potential Justify Buy Rating - TipRanks
1.95%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):